Primary Neurolymphomatosis: A Literature Review
European Journal of Neurology · 2025-04 · 32 (4)
DOI: 10.1111/ene.70173 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neurology, online erschienen am 23.04.2025. Verfasst von Sahar Chakroun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Service de Physiologie Clinique-Explorations Fonctionnelles, AP-HP, DMU DREAM, Hôpital Lariboisière, Paris, France. Hauptthemen laut MEDLINE: Neurolymphomatosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Primary neurolymphomatosis (PNL) is a rare clinical entity resulting from direct lymphomatous infiltration into the peripheral nervous system. Its diagnosis is challenging as the hematological condition is unknown at the onset of neurological symptoms.
Methods
We report two of our own cases and the first extensive review of published cases of PNL to delineate its clinical features, paraclinical investigation results, progression, and treatment response more precisely. We extracted demographic data, clinical presentation, results of the investigations performed, type and number of treatments, overall survival, and progression‐free survival.
Results
We describe 301 cases of PNL in patients with a mean age of 57.9 years, 61% of whom were men. The most common clinical presentation was an often painless asymmetric neuropathy. Other presentations included multifocal neuropathy preferentially affecting the sciatic and peroneal nerves, radiculopathy, brachial plexus lesions, cauda equina syndrome, and cranial nerve palsy. Systemic signs and deterioration of clinical status were uncommon. Diagnosis was established after a median of 8 months, based on histological results (76%) or a cluster of elements in cases of positive PET findings. A B‐cell lymphoma was diagnosed in 73% of cases. Systemic chemotherapy (90%) and rituximab (60%) were the most common treatments, with a response rate of 45%. Relapse occurred in 24% of patients, and 55% ultimately died from PNL. Overall survival was 28 months. Type of treatment was not associated with survival.
Conclusions
This literature review provides an overview of the available data concerning PNL presentation and progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service de Physiologie Clinique-Explorations Fonctionnelles, AP-HP, DMU DREAM, Hôpital Lariboisière, Paris, France.
- Service de Neurologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.
- Service D'immuno Pathologie Clinique, Hôpital Saint Louis, APHP, Paris, France.
- Université Paris Cité, INSERM UMR-S1144, Optimisation Thérapeutique en Neuropsychopharmacologie, Faculté de Pharmacie de Paris, Paris, France.
- Centre de Compétence Neuropathies Rares et Amyloïdes Ile-de France Caraïbes (CERAMIC), FILNEMUS, AP-HP, DMU DREAM, Hôpital Lariboisière, Paris, France.
ORCID-Profile: Pierre Lozeron
Zitieren
APA
Chakroun, S., Faucher, A., Gueguen, A., Fadlallah, J., Corvilain, E., Kubis, N., & Lozeron, P. (2025). Primary Neurolymphomatosis: A Literature Review. European Journal of Neurology, 32(4). https://doi.org/10.1111/ene.70173
Vancouver
Chakroun S, Faucher A, Gueguen A, Fadlallah J, Corvilain E, Kubis N, et al. Primary Neurolymphomatosis: A Literature Review. European Journal of Neurology. 2025;32(4). doi:10.1111/ene.70173
BibTeX
@article{Chakroun2025,
author = {Chakroun, Sahar and Faucher, Alice and Gueguen, Antoine and Fadlallah, Jehane and Corvilain, Emilie and Kubis, Nathalie and Lozeron, Pierre},
title = {Primary Neurolymphomatosis: A Literature Review},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {4},
doi = {10.1111/ene.70173}
}
EUVIMED